



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/584,481	06/23/2006	Tsuneo Yasuma	2006_0878A	9103
513	7590	11/14/2007	EXAMINER	
WENDEROTH, LIND & PONACK, L.L.P. 2033 K STREET N. W. SUITE 800 WASHINGTON, DC 20006-1021			SOLOLA, TAOFIQ A	
		ART UNIT	PAPER NUMBER	
		1625		
		MAIL DATE	DELIVERY MODE	
		11/14/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/584,481	YASUMA ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Taofiq A. Solola	1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on \_\_\_\_\_.
- 2a) This action is **FINAL**.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-16 and 18-20 is/are pending in the application.
  - 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-16 and 18-20 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All    b) Some \* c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                  | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application |
|   | 6) <input type="checkbox"/> Other: _____                          |

Art Unit: 1625

Claims 1-16, 18-20 are pending in this application.

Claim 17 is cancelled.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-16, 18-20 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims lack adequate support in the specification. The term "hydrocarbon group" is not defined in the specification so as to ascertain structures of the compounds included and/or excluded by the term. It is defined by examples, which themselves are defined by examples. However, "[e]xemplification is not an explicit definition." The specification must set forth the definition explicitly and clearly, with reasonable clarity, deliberateness and precision, *Teleflex Inc. v. Ficosa North Am Corp.*, 63 USPQ2d 1374, (Fed. Cir. 2002), *Rexnord Corp. v. Laitram Corp.*, 60 USPQ2d 1854 (Fed. Cir. 2001).

The term "prodrug" in claims 3, 12-16, 18, is not defined in the specification so as to ascertain the structures of compounds that are included and/or excluded by the terms. By deleting the term the rejection would be overcome. Claims 12-16 and 18 are drawn to all disorders modulator of GPR40: mechanism by which the compounds work in the body. This is not a practical utility under the US patent practice. To ascertain the practical utility, one must read the specification into the claims contrary to several precedent decisions by the US courts

and Official practice. The claims are attempts by applicant to claim treatment of all diseases known today and that may be discovered in the future, arising from the mechanism. They are reach-through claims and are no longer patentable under the US patent practice. A claim must stand alone to define the invention, and incorporation into the claims by reference to the specification or an external source is not permitted. Ex parte Fressola, 27 USPQ 2d 1608, BdPatApp & Inter. (1993). Applicant must show possession of the invention by describing it with all the claimed limitations. *Lookwood v. American Airlines Inc.* 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (Fed Cir. 1997). By deleting the claims the rejection would be overcome.

Claims 3, 12-16, 18 are rejected under 35 U.S.C. 112, first paragraph, because the specification does not reasonably provide enablement for using the compounds as prodrugs, for prevention (prophylaxis) and the claimed mechanism. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

"In the context of determining whether sufficient "utility as a drug, medicant, and the like in human therapy" has been alleged, It is proper for the examiner to ask for substantiating evidence unless one with ordinary skill in the art would accept the [compounds and the utilities] as obviously correct." *In re Jolles*, 628 F.2d 1327, 1332 (Fed. Cir. 1980), citing *In re Novak*, 306 F.2d 924 (CCPA 1962); see 340 F.2d 974, 977-78 (CCPA 1965).

"A specification disclosure which contains a teaching of the manner and process of making and using the invention . . . must be taken as in compliance with the enabling requirement of the first paragraph of § 112 unless there is reason to doubt the objective truth of the statements contained therein which must be relied on for enabling support." *In re Brana*, 51 F.3d 1560 (Fed. Cir. 1995), Id. at 1566, quoting *Marzocchi*, 439 F.2d 220, 223 (CCPA 1971); *Fiers v. Revel*, 984 F.2d 1164, 1171-72 (Fed. Cir. 1993), quoting *Marzocchi*, 439 F.2d at 223;

see also *Armbruster*, 512 F.2d 676, 677 (CCPA 1975); *Knowlton*, 500 F.2d 566, 571 (CCPA 1974); *Bowen*, 492 F.2d 859 (CCPA 1974); *Hawkins*, 486 F.2d 569, 576 (CCPA 1973).

Where there is “no indication that one skilled in the art would accept without question [the instant compounds and method of use] and no evidence has been presented to demonstrate that the claimed products do have those effects *Novak*, 306 F.2d at 928, an applicant has failed to sufficiently demonstrate sufficient utility and therefore cannot establish enablement.” *In re Rasmusson*, 75 USPQ2d 1297 (CAFC 2005). The claimed invention is not enabled without undue experimentation for the following reasons:

For rejection under 35 U.S.C. 112, first paragraph, the following factors must be considered. *In re Wands*, 8 USPQ2d 1400, 1404 (CAFC, 1988): The factors are a) the breadth of the claims, b) the nature of the invention, c) the state of the prior art, d) the relative skill of those in that art, e) the predictability or unpredictability of the art, f) the amount of direction or guidance presented, g) the presence or absence of working examples, and h) the quantity of experimentation necessary, *In re Rainer*, 146 USPQ 218 (1965); *In re Colianni*, 195 USPQ 150, *Ex parte Formal*, 230 USPQ 546. The breath of the claims includes all compounds of formula I. The compounds embraced by the claims are so numerous and are in the hundreds of thousands or millions. The nature of the invention is making and using the compounds as pharmaceuticals. Applicant claims all hydrocarbon groups, which are defined in the specification by examples.

The specification fails to disclose how a “normal” human predisposed to all the diseases from modification of GPR40 receptor would be identified and how each of the diseases could be prevented.

As for mechanisms, it is quite possible that a mutation in the gene responsible for GPR40 receptor may lead to increase or decrease level. To use the invention as claimed, one

Art Unit: 1625

of ordinary skill in the art would have to perform experimentation in every instance to determine if the increase or decrease is due to genetic mutation in a patient or not. After prospective patients are identified and treated, assays must be performed on each one to determine if treatment is successful. However, the specification fails to disclose routine procedures to perform such assays. Therefore, to make and use the instant invention, one of ordinary skill in the art would have to perform significant amount of experimentation. Such is deemed undue experiment under the US patent practice.

Finding a prodrug is an empirical exercise. Predicting if a certain ester of a claimed alcohol, for example, is in fact a prodrug, that produces the active compound metabolically, in man, at a therapeutic concentration and at a useful rate is filled with experimental uncertainty.

Although attempts have been made to predict drug metabolism *de novo*, this is still an experimental science. For a compound to be a prodrug, it must meet three tests. It must itself be biologically inactive. It must be metabolized to a second substance in a human at a rate and to an extent to produce that second substance at a physiologically meaningful concentration. Thirdly, that second substance must be clinically effective. Determining whether a particular compound meets these three criteria requires a large quantity of experimentation. Wolff (Medicinal Chemistry) summarizes the state of the prodrug art in Wolff, Manfred E. "Burger's Medicinal Chemistry, 5ed, Part I", John Wiley & Sons, 1995, pages 975-977. The table on the left side of page 976 outlines the research program to be undertaken to find a prodrug. The second paragraph in section 10 and the paragraph spanning pages 976-977 indicate the low expectation of success. In that paragraph the difficulties of extrapolating between species are further developed.

Since, the prodrug concept is a pharmacokinetic issue, the lack of any standard pharmacokinetic protocol in the specification is particularly relevant. Banker, G.S. et al, "Modern

Pharmaceutics, 3ed.", Marcel Dekker, New York, 1996, pages 451 and 596, in the first sentence, third paragraph on page 596 states that "extensive development must be undertaken" to find a prodrug. Wolff (Medicinal Chemistry) in the last paragraph on page 975 describes the artisans making prodrugs as collaborative team of synthetic pharmaceutical chemists and metabolism experts. It is well established that "the scope of enablement varies inversely with the degree of unpredictability of the factors involved", and physiological activity is generally considered to be an unpredictable factor. See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The specification fails to disclose any study of prodrugs of the instant compounds.

The predictability or lack thereof in the art refers to the ability of one skilled in the art to extrapolate the disclosed or known results to the claimed invention. In the instant invention, the amount of direction and guidance provided by applicant is limited.

There is no evidence in the specification that established nexus between the disclosure and the instantly claimed invention. See *Ex parte Mass*, 9 USPQ2d 1746, (1987).

MPEP 2164.01(a) states, "[a] conclusion of lack of enablement means that, based on the evidence regarding any of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion is clearly justified here. By deleting solvate in every occurrence and claims 6-10 the rejection would be overcome.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Claims 1-16, 18-20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. For the reason set forth above under 35 USC 112, first

Art Unit: 1625

paragraph, the claims are indefinite. Applicant must show possession of the invention by describing it with all the claimed limitations. *Lookwood v. American Airlines Inc.* 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (Fed Cir. 1997).

Claim 3 improperly depends from claim 1 for failure to limit the scope of 1. Also, it expands the scope of 1 by citing "prodrug".

Claims 15 and 16 are duplicates. Under the US patent practice the compositions are the same irrespective of how made. Also, making the composition in claims 15 and 16 without setting forth the steps of how it is made is not an invention under the US patent practice. The intended uses cited in both claims are not limitations under the US patent practice. By deleting the claims the rejection would be overcome.

The term "prodrug" in claims 3, 12-16, 18, lack proper antecedent basis in claim 1. Claims 19-20 are independent claims and therefore cannot rely on claim 1 for the definition of the substituents. Appropriate correction is required.

#### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-16, 18-20 are rejected under 35 U.S.C. 102(b) as being anticipated by Kohji et al., WO 2004041266 (submitted by applicant).

Kohji et al., disclose compound in the attached abstract wherein R4, R5, R10, R11 are H, E is N or bond, one of W1 and W2 is a bond the other is CH<sub>2</sub>, or alkyl, R6 is alkyl or hydrocarbon group their composition and method of use as GPR40 receptor controlling agent.

Art Unit: 1625

See the attached abstract. By filing certified English translation of the priority arts the rejection would be overcome.

***Telephone Inquiry***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taofiq A. Solola, PhD. JD., whose telephone number is (571) 272-0709. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on (571) 272-0867. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.



TAOFIQ SOLOLA  
PRIMARY EXAMINER

Group 1625

October 27, 2007